Table 1.
Main patient characteristics.
| Characteristics | Cohort 1 (n = 165) | Cohort 2 (n = 548) | Overall (n = 713) |
|---|---|---|---|
| Sex | |||
| Male | 120 (72.7%) | 478 (87.2%) | 598 (83.9%) |
| Female | 45 (27.3%) | 70 (12.8%) | 115 (16.1%) |
| Age | |||
| Median [IQR] | 63.8 [56.2–70.0] | 61.0 [55.8–67.0] | 62.0 [56.0–68.0] |
| (Range) | (37.5–85.1) | (40.0–79.0) | (37.5–85.1) |
| Race | |||
| Asian | 0 | 548 (100%) | 548 (76.9%) |
| White | 165 (100%) | 0 | 165 (23.1%) |
| Smoking (yes) | 158 (95.8%) | 440 (80.3%) | 598 (83.9%) |
| WHO performance score | |||
| 0 | 43 (26.4%) | 87 (15.9%) | 130 (18.3%) |
| 1 | 89 (54.6%) | 446 (81.4%) | 535 (75.2%) |
| 2 | 31 (19.0%) | 15 (2.7%) | 46 (6.5%) |
| Missing | 2 | 0 | 2 |
| Histological type | |||
| Adenocarcinoma | 111 (67.3%) | 284 (51.8%) | 395 (55.4%) |
| Squamous cell carcinoma | 25 (15.2%) | 254 (46.4%) | 279 (39.1%) |
| Poorly differentiated carcinoma | 29 (17.6%) | 10 (1.8%) | 39 (5.5%) |
| Stage | |||
| IIIC | 0 (0.0%) | 87 (15.9%) | 87 (12.2%) |
| IV | 165 (100.0%) | 461 (84.1%) | 626 (87.8%) |
| Main sites or metastases | |||
| Brain | 55 (33.7%) | 71 (13.0%) | 126 (17.7%) |
| Liver | 35 (21.2%) | 48 (8.8%) | 83 (11.6%) |
| Bone | 76 (46.1%) | 163 (29.7%) | 239 (33.5%) |
| Number of metastatic sites | |||
| Median [IQR] | 3 [2–4] | 1 [1–2] | 2 [1–2] |
| (Range) | (1–11) | (0–5) | (0–11) |
| PD-L1 tumour proportion score | |||
| <1% | 59 (37.6%) | 97 (25.3%) | 156 (28.9%) |
| 1%–49% | 56 (35.7%) | 149 (38.9%) | 205 (38.0%) |
| ≥50% | 42 (26.8%) | 137 (35.8%) | 179 (33.1%) |
| Missing | 8 | 165 | 173 |
| Chemotherapy regimen administered | |||
| Pemetrexed + Carboplatin | 122 (73.9%) | 222 (40.5%) | 344 (48.2%) |
| Paclitaxel + Carboplatin | 40 (24.2%) | 326 (59.5%) | 366 (51.3%) |
| Pemetrexed + Cisplatin | 3 (1.8%) | 0 (0.0%) | 3 (0.4%) |
| Immune checkpoint inhibitor regimen administered | |||
| Pembrolizumab | 165 (100.0%) | 195 (35.6%) | 360 (50.5%) |
| Sintilimab | 0 (0.0%) | 202 (36.9%) | 202 (28.3%) |
| Toripalimab | 0 (0.0%) | 43 (7.8%) | 43 (6.0%) |
| Tirelizumab | 0 (0.0%) | 55 (10.0%) | 55 (7.7%) |
| Camrelizumab | 0 (0.0%) | 53 (9.7%) | 53 (7.4%) |
| Median time of day when the first four ICI infusions were administered per patient (clock hours, hh:mm) | |||
| Median [IQR] | 10:39 [9:56–11:30] | 11:51 [11:12–13:37] | 11:36 [10:49–12:48] |
| (Range) | (8:53–16:59) | (9:16–18:11) | (8:53–18:11) |
| Within-patient coefficient of variation of time of ICI infusion (%) | |||
| Median [IQR] | 6.4 [3.5–11.1] | 11.2 [5.9–19.8] | 9.9 [5.2–18.1] |
| (Range) | (0–33) | (0–35) | (0–35) |
| Number of ICI + chemotherapy courses per patient | |||
| Median [IQR] | 4 [3–4] | 4 [4–6] | 4 [4–5] |
| (Range) | (1–6) | (1–26) | (1–26) |
| Total number of ICI infusions (±chemotherapy) administered per patient | |||
| Median [IQR] | 7 [3–14] | 13.5 [6–19] | 9 [5–18] |
| (Range) | (1–49) | (1–40) | (1–49) |
| N of patients with local radiotherapy post ICI-chemotherapy (%) | 47 (28.5%) | 27 (4.9%) | 74 (10.4%) |
IQR, interquartile range.